Figures & data
Figure 1 SEM image of SMV–ALA NPs.
![Figure 1 SEM image of SMV–ALA NPs.](/cms/asset/34e3a884-b78c-4c2e-88b3-05d747e53413/dddt_a_12173071_f0001_b.jpg)
Figure 2 (A) Individual NIR spectra of plasma, SMV, ALA, and test. (B) Raw NIR spectra of plasma at different time intervals after SMV oral administration.
![Figure 2 (A) Individual NIR spectra of plasma, SMV, ALA, and test. (B) Raw NIR spectra of plasma at different time intervals after SMV oral administration.](/cms/asset/0cf89e9c-a9f0-4fd1-a552-275997ffbb5a/dddt_a_12173071_f0002_c.jpg)
Figure 3 Calibration curve for SMV content in mice plasma.
![Figure 3 Calibration curve for SMV content in mice plasma.](/cms/asset/1c306d63-088f-445a-8227-5a866240222b/dddt_a_12173071_f0003_c.jpg)
Table 1 Concentrations of SMV plain and SMV–ALA NPs in mice plasma obtained by HPLC and NIR
Figure 4 Relative error for SMV in mice plasma obtained by NIR.
![Figure 4 Relative error for SMV in mice plasma obtained by NIR.](/cms/asset/e180e42c-d7f2-4ede-9ae6-aca830b6c9c5/dddt_a_12173071_f0004_b.jpg)
Table 2 Estimated pharmacokinetics of SMV plain and SMV–ALA NPs in mice plasma obtained by HPLC and NIR